Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes

NCT02005848 is registered in ClinicalTrials.gov with Kamada, Ltd. as lead sponsor.

NCT NCT02005848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02005848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes
Lead sponsor
Kamada, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
February 28, 2017
Enrollment
70 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

new onset type-1 diabetes